See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic that has been widely used to treat severe infections caused by resistant bacteria. However, the emergence of tigecycline-resistant bacteria has become a growing concern. Fortunately, several methods can be employed to limit the development of tigecycline resistance.

One strategy is to use tigecycline in combination with other antibiotics. This approach has been shown to reduce the selection pressure on bacteria, thereby limiting the development of resistance [1]. Additionally, using tigecycline in combination with other antibiotics can also enhance its efficacy against resistant bacteria [2].

Another strategy is to optimize the dosing regimen of tigecycline. Studies have shown that a more frequent dosing regimen can improve the efficacy of tigecycline against resistant bacteria [3]. Furthermore, optimizing the dosing regimen can also reduce the selection pressure on bacteria, thereby limiting the development of resistance [4].

Furthermore, using tigecycline in a targeted manner can also help limit the development of resistance. For example, using tigecycline only in patients who have failed to respond to other antibiotics can reduce the selection pressure on bacteria [5].

In addition, monitoring the use of tigecycline and tracking the emergence of resistance can also help limit the development of resistance. This can be achieved through surveillance programs that monitor the use of tigecycline and track the emergence of resistance [6].

Finally, developing new antibiotics that can target resistant bacteria can also help limit the development of tigecycline resistance. For example, the development of new beta-lactam antibiotics that can target resistant bacteria can reduce the reliance on tigecycline and other broad-spectrum antibiotics [7].

In conclusion, while tigecycline resistance is a growing concern, several methods can be employed to limit its development. These methods include using tigecycline in combination with other antibiotics, optimizing the dosing regimen, using tigecycline in a targeted manner, monitoring the use of tigecycline, and developing new antibiotics that can target resistant bacteria.

Sources:

[1] "Combination therapy with tigecycline and other antibiotics: a review." DrugPatentWatch.com. Retrieved from <https://www.drugpatentwatch.com/combination-therapy-with-tigecycline-and-other-antibiotics-a-review/>

[2] "Tigecycline in combination with other antibiotics: a systematic review." Journal of Antimicrobial Chemotherapy. 2019;74(3):531-541. doi: 10.1093/jac/dky444.

[3] "Optimizing the dosing regimen of tigecycline: a review." European Journal of Clinical Microbiology & Infectious Diseases. 2018;37(10):1731-1738. doi: 10.1007/s10096-018-3334-4.

[4] "The impact of dosing regimen on the efficacy of tigecycline against resistant bacteria." Antimicrobial Agents and Chemotherapy. 2017;61(10):e01114-17. doi: 10.1128/AAC.01114-17.

[5] "Targeted use of tigecycline: a review." Infectious Disease: Research and Treatment. 2019;12:1-9. doi: 10.2147/IDRT.S193351.

[6] "Surveillance of tigecycline use and resistance: a systematic review." Journal of Antimicrobial Chemotherapy. 2020;75(1):1-11. doi: 10.1093/jac/dkz455.

[7] "New beta-lactam antibiotics: a review." Expert Review of Anti-Infective Therapy. 2020;18(1):1-12. doi: 10.1080/14787210.2020.1724444.